Skip to main content

AbbVie vs Amgen: Revenue, Profit and Business Model

AbbVie had $61.2B of annual revenue in FY2025 and $4.2B of net income. Amgen had $36.8B of annual revenue in FY2025 and $7.7B of net income.

Latest financial snapshot

AbbVie

Latest annual revenue
$61.2B (FY2025)
Net income
$4.2B
Net margin
6.9%
Revenue growth
+10.1% a year, FY2016–FY2025

Amgen

Latest annual revenue
$36.8B (FY2025)
Net income
$7.7B
Net margin
21.0%
Revenue growth
+5.4% a year, FY2016–FY2025

Financial summary

AbbVie

AbbVie reported $61.160 billion of FY2025 net revenue and $4.226 billion of net income. Skyrizi and Rinvoq generated $25.866 billion combined, while Humira declined to $4.540 billion after U.S. biosimilar entry. The 2020 Allergan acquisition added neuroscience and aesthetics revenue, and the 2024 ImmunoGen and Cerevel acquisitions added oncology and neuroscience assets. AbbVie is a dominant biopharmaceutical company, sustaining a massive market valuation often exceeding $250 billion, heavily driven by its blockbuster immunology and aesthetics portfolios.

Amgen

Amgen is a cash-generative business with high product gross margins. In fiscal 2025 it reported US$36.8 billion of total revenues, US$7.7 billion of GAAP net income, a 25.8% GAAP operating margin, US$8.1 billion of free cash flow and US$5.1 billion of dividends paid. Its results used to depend on a few large franchises, first Epogen and Aranesp, then Enbrel. As those matured Amgen bought revenue instead: Onyx in 2013, Otezla in 2019 and Horizon Therapeutics for US$27.8 billion in 2023. That last deal is also the main reason for the balance sheet it now carries, with US$54.6 billion of debt outstanding at December 31, 2025, debt leverage of about 3.2 times EBITDA and US$2.8 billion of net interest expense in fiscal 2025. Amgen Inc. is one of the world's largest independent biotechnology companies, holding a massive market valuation often exceeding $150 billion.

Revenue and profit by year

AbbVie

AbbVie revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$61.2B$4.2B6.9%+8.6%Source
FY2024$56.3B$4.3B7.6%+3.7%Source
FY2023$54.3B$4.9B9.0%-6.4%Source
FY2022$58.1B$11.8B20.4%+3.3%Source
FY2021$56.2B$11.5B20.5%+22.7%Source
FY2020$45.8B$4.6B10.1%+37.7%Source
FY2019$33.3B$7.9B23.7%+1.6%Source
FY2018$32.8B$5.7B17.4%+16.1%Source
FY2017$28.2B$5.3B18.8%+10.1%Source
FY2016$25.6B$6B23.2%—Source
Full AbbVie financials

Amgen

Amgen revenue, net income, margin and growth by fiscal year
YearRevenueNet incomeMarginGrowthSource
FY2025$36.8B$7.7B21.0%+10.0%Source
FY2024$33.4B$4.1B12.2%+18.6%Source
FY2023$28.2B$6.7B23.8%+7.1%Source
FY2022$26.3B$6.6B24.9%+1.3%Source
FY2021$26B$5.9B22.7%+2.2%Source
FY2020$25.4B$7.3B28.6%+8.8%Source
FY2019$23.4B$7.8B33.6%-1.6%Source
FY2018$23.7B$8.4B35.3%+3.9%Source
FY2017$22.8B$2B8.7%-0.6%Source
FY2016$23B$7.7B33.6%—Source
Full Amgen financials

Where the revenue comes from

AbbVie

  • Immunology Portfolio49.7%

    FY2025 revenue was $30.406 billion, led by Skyrizi, Rinvoq, and Humira.

  • Neuroscience Portfolio17.6%

    FY2025 revenue was $10.767 billion, including Vraylar, Botox Therapeutic, Ubrelvy, and Qulipta.

  • Oncology Portfolio10.9%

    FY2025 revenue was $6.655 billion, including Imbruvica, Venclexta, and Elahere.

  • Aesthetics Portfolio7.9%

    FY2025 revenue was $4.860 billion, including Botox Cosmetic and Juvederm.

  • Other Products and Revenue13.9%

    The remaining FY2025 revenue came from eye care, other specialty products, and other revenue.

Amgen

  • U.S. product sales

    ~70% of total revenues

    United States product sales were US$25.66 billion in fiscal 2025, 73% of the US$35.15 billion product sales total and about 70% of total revenues. The largest domestic contributors were Prolia (US$2.98 billion), Enbrel (US$2.20 billion), Otezla (US$1.84 billion), Tepezza (US$1.76 billion), Repatha (US$1.66 billion), Evenity (US$1.60 billion) and Tezspire (US$1.48 billion). Access depends on formulary placement with the large pharmacy benefit managers and on Medicare and Medicaid reimbursement.

  • International product sales

    ~26% of total revenues

    Product sales outside the United States were US$9.49 billion in fiscal 2025, 27% of product sales. The largest were Repatha (US$1.35 billion), Aranesp (US$973 million), XGEVA (US$729 million), Vectibix (US$571 million) and Amgevita (US$549 million). Prices are generally lower than in the United States because of government reference pricing and national formulary negotiation.

  • Biosimilars

    ~8% of total revenues

    Biosimilars sit inside product sales and generated about US$3.0 billion in fiscal 2025: Mvasi (bevacizumab) US$771 million, Pavblu (aflibercept) US$700 million, Amjevita and Amgevita (adalimumab) US$597 million, Wezlana and Wezenla (ustekinumab) US$273 million, and US$683 million across the smaller biosimilars reported within other products. Amjevita sales fell 22% year over year, so segment growth now comes from the newer launches.

  • Rare disease portfolio acquired with Horizon

    ~13% of total revenues

    Also inside product sales, the medicines acquired with Horizon Therapeutics produced about US$4.6 billion in fiscal 2025: Tepezza US$1.90 billion, Krystexxa US$1.34 billion, Uplizna US$655 million and the ultra-rare products US$719 million. Uplizna grew 73% after approvals in IgG4-related disease and generalized myasthenia gravis, while the ultra-rare group fell 5% as Ravicti met generic competition.

  • Other revenues

    ~4% of total revenues

    Other revenues, mainly royalties, license income and corporate partner payments, were US$1.60 billion in fiscal 2025, the difference between US$36.75 billion of total revenues and US$35.15 billion of product sales. The line carries high margins but is not a growth priority.

Business model and strategy

AbbVie

How it makes money

AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Formed in 2013 as a spin-off from Abbott Laboratories, AbbVie built its initial commercial empire around Humira (adalimumab)—historically the world's best-selling biologic medicine.

Growth strategy

AbbVie is expanding approved uses and commercial reach for Skyrizi and Rinvoq while investing in oncology and neuroscience. ImmunoGen added Elahere and antibody-drug conjugate programs, Cerevel added clinical-stage neuroscience programs, and Allergan added Botox, Vraylar, migraine products, eye care, and aesthetics.

Competitive advantage

AbbVie's durable competitive moat is built upon its world-class commercial execution in immunology, unmatched patent estate design, and the high-margin cash flow engine of the Allergan aesthetics portfolio.

AbbVie business model in full

Amgen

How it makes money

Amgen operates a high-risk, high-reward biopharmaceutical business model. It spends heavily on research to discover and engineer new biologic drugs: US$7.3 billion in fiscal 2025, or 20.7% of product sales. Once a drug is approved by the FDA, Amgen secures a patent, granting them a temporary monopoly to sell the drug at a premium price.

Growth strategy

Amgen's growth plan has two parts: scale the newer medicines and buy what the pipeline does not supply. Recent launches and acquired products drove the 10% revenue growth in fiscal 2025, with Tezspire up 52% to US$1.48 billion, Repatha up 36% to US$3.02 billion, Evenity up 34% to US$2.10 billion, Uplizna up 73% to US$655 million and Imdelltra reaching US$627 million in its second year.

Competitive advantage

Amgen's main competitive advantage is experience making complex biologics at commercial scale, which it has done continuously since Epogen launched in 1989.

Amgen business model in full

Questions about AbbVie vs Amgen

Which company has higher revenue — AbbVie Inc. or Amgen Inc.?

AbbVie Inc. had $61.2B (FY2025), while Amgen Inc. had $36.8B (FY2025). By latest annual revenue, AbbVie Inc. is the larger business, with Amgen Inc. showing a smaller revenue base.

What is the market cap of AbbVie Inc. vs Amgen Inc.?

AbbVie Inc.'s market capitalisation stands at $465.8B, while Amgen Inc.'s is $228.2B. AbbVie Inc. carries the higher market valuation, reflecting investors' expectations of its future earnings power relative to Amgen Inc..

How does revenue per employee compare for AbbVie Inc. and Amgen Inc.?

AbbVie Inc. has $1.07M / employee in revenue per employee, while Amgen Inc. has $1.17M / employee. Headcounts may use different dates, so the ratio alone does not establish which business operates more efficiently.

How do AbbVie Inc. and Amgen Inc. make money?

AbbVie Inc. and Amgen Inc. generate revenue in fundamentally different ways. AbbVie Inc.: AbbVie Inc. is a global biopharmaceutical research and development company that discovers, manufactures, and markets advanced medicines across immunology, oncology, neuroscience, and aesthetic medicine. Amgen Inc.: Amgen operates a high-risk, high-reward biopharmaceutical business model.

Which company is valued higher relative to revenue — AbbVie Inc. or Amgen Inc.?

On a price-to-sales (P/S) basis, AbbVie Inc. trades at 7.6x P/S and Amgen Inc. at 6.2x P/S. AbbVie Inc. commands a higher revenue multiple, typically indicating that investors expect faster growth or higher future margins compared to Amgen Inc.. A higher multiple is not inherently better — it may also signal that the stock is priced for perfection.

Is AbbVie Inc. bigger than Amgen Inc.?

By last reported revenue, AbbVie Inc. ($61.2B (FY2025)) is the larger company compared to Amgen Inc. ($36.8B (FY2025)). Revenue scale is one dimension of size — market capitalisation, employee count, and geographic reach are also relevant depending on the context.

Figures come from each company's filings and the sources linked beside them. Amounts reported in another currency are shown in US dollars at an approximate rate and marked with ~. Back to the AbbVie vs Amgen overview

Content is for informational purposes only. Not financial advice. Data sourced from SEC filings, annual reports, and public records. See our full disclaimer and methodology.